The initial success of Sildenafil undeniably revolutionized the pharmaceutical landscape, but placing funds in companies primarily reliant on unbranded versions presents a uncertain picture. Although early returns were substantial, the cessation of patents and the appearance of cheaper alternatives have weakened market share. Consequently, a thorou